|
|
|
|
|
07.01.26 - 18:03
|
GENFIT Announces 2026 Financial Calendar (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026....
|
|
|
06.01.26 - 18:15
|
GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 6, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that G1090N – a small molecule and the Company's lead investigational drug candidate for Acute-On-Chronic Liver Failure (ACLF) – demonstrated a favorable Phase 1 safety profile, and a strong anti-inflammatory activity in ex-vivo studies....
|
|
|
10.12.25 - 18:03
|
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 10, 2025 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today reports encouraging preliminary Phase 1b data from its CCA clinical trial evaluating GNS561 in combination....
|
|
|
|
|
|
|
|
|
|
|
|
|
10.11.25 - 07:33
|
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025 (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today presents promising new preclinical data in ACLF at The Liver Meeting® 2025 with nitazoxanide (NTZ). GENFIT is advancing NTZ through a novel formulation, investigational drug G1090N, which serves as the cornerstone of our ACLF pipeline and reflects our commitment to addressing critical unmet needs in liver disease. G1090N was designed to optimize dose-response and permit sufficient dosing flexibility in patients with ACLF, who are known to have varying degrees of renal or hepatic impairment or failure....
|
|
|
28.10.25 - 22:15
|
GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025 (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), October 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its participation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 in Washington, D.C., November 7-11, 2025....
|
|
|
|
|
|
|
|
|
|
|
|
|
04.09.25 - 23:51
|
XETR: NEW INSTRUMENT AVAILABLE - 05.09.2025 - FR0004163111 (XETRA)
|
|
|
Das Instrument XUP FR0004163111 GENFIT S.A. EO -,25 EQUITY hat seinen ersten Handelstag am 05.09.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG FRA0, SettlCurr EUR, CCP Y
The instrument XUP FR0004163111 GENFIT S.A. EO -,25 EQUITY has its first trading date on 05.09.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG FRA0, SettlCurr EUR, CCP Y...
|
|
|
|
|
17.06.25 - 20:33
|
GENFIT: June 17, 2025 Combined Shareholders Meeting Results (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders approved all of the resolutions, with the exception of resolution n°28 which was rejected in accordance with the recommendations of the Board of Directors....
|
|
|
22.05.25 - 22:15
|
GENFIT Reports First Quarter 2025 Financial Information (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2025 and revenues for the first three months of 2025.1...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
